BioSpace

Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers

The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.

By BioSpace

1 min read
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights